Features | Partner Sites | Information | LinkXpress
Sign In
JIB
BioConferenceLive
GLOBETECH PUBLISHING

Beckman Coulter Life Sciences Acquires Blue Ocean Biomedical

By BiotechDaily International staff writers
Posted on 18 Apr 2012
Beckman Coulter Life Sciences (Indianapolis, IN, USA) has acquired Blue Ocean Biomedical, LLC (Pembroke Pines, FL, USA), manufacturer of automated flow cytometry systems and reagents. The transaction provides Beckman Coulter Life Sciences with low complexity analyzers that integrate automated sample preparation and directly address emerging flow cytometry-market trends.

Driving growth through internal product development and through acquisition of differentiated businesses and technologies is a core strategy for Beckman Coulter Life Sciences. The transaction expands the company’s flow cytometry line and targets routine clinical analyses. Blue Ocean Biomedical products complement the company’s existing cytometry portfolio with instruments based on a “sample in, result out” (SIRO) approach that represents a fundamental change in the routine clinical analysis sector.

“This acquisition provides both immediate opportunity and long-term value,” said Scott Atkin, president, Beckman Coulter Life Sciences. “The simplification of customer workflows will be dramatic. We’ll be able to offer customers an extended line of market leading technology while expanding our reach within a key segment for flow cytometry.”

Blue Ocean Biomedical products provide the first true integration of sample preparation, handling, analysis and data management, and the only SIRO solution for clinical flow cytometry, and will enable Beckman Coulter Life Sciences to deliver an expanding portfolio of clinical testing to a broader global market.

“Our team has developed a line of truly unique instrument systems: essentially, the world’s first ‘load & go’ flow cytometers,” said Mike Brochu, CEO and cofounder of Blue Ocean Biomedical. “With its history of leadership and innovation in this field, Beckman Coulter has all the resources and technology needed to build on this platform and future systems for years to come.”

Related Links:
Beckman Coulter
Blue Ocean Biomedical




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).

Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel

Precise Ion Irradiation Dosing Method Developed for Cancer Therapy

Scientists are employing nuclear physics principles to provide more effective approaches to radiotherapy treatment for cancer patients. Radiation therapy using heavy ions is best suitable for cancer patients with tumors that are difficult to access, such as in the brain. These particles scarcely damage the penetrated... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.